T cell costimulation protects obesity-induced adipose inflammation and insulin resistance
- Jixin Zhong1,
- Xiaoquan Rao1,
- Zachary Braunstein4,
- Anne Taylor2,
- Vimal Narula2,
- Jeffrey Hazey2,
- Dean Mikami2,
- Bradley Needleman2,
- Jessica Rutsky4,
- Qinghua Sun4,
- Jeffrey A. Deiuliis1,
- Abhay R. Satoskar3 and
- Sanjay Rajagopalan1,*
- 1Division of Cardiology, Department of Medicine, University of Maryland School of Medicine;
- 2Department of Surgery, The Ohio State University;
- 3Division of Experimental Pathology, The Ohio State University;
- 4Davis Heart and Lung Research Institute, The Ohio State University.
- *Corresponding author: Sanjay Rajagopalan, E-mail: ( )
A key pathophysiologic role for activated T cells in mediating adipose inflammation and insulin resistance has been recently postulated. However, mechanisms underlying their activation are poorly understood. In this study, we demonstrated a previously unrecognized homeostatic role for the costimulatory B7 molecules (CD80 and CD86) in preventing adipose inflammation. Instead of promoting inflammation which was found in many other disease conditions, B7 costimulation reduced adipose inflammation by maintaining regulatory T cells (Tregs) number in adipose tissue. In both humans and mice, expression of CD80 and CD86 was negatively correlated with the degree of insulin resistance and adipose tissue macrophage infiltration. Decreased B7 expression in obesity appeared to directly impair Treg proliferation and function that lead to excessive pro-inflammatory macrophages and the development of insulin resistance. CD80/CD86 double knockout (B7 KO) mice had enhanced adipose macrophage inflammation and insulin resistance under both high-fat and normal diet conditions, accompanied by reduced Treg development and proliferation. Adoptive transfer of Tregs reversed insulin resistance and adipose inflammation in B7 KO mice. Our results suggest an essential role for B7 in maintaining Tregs and adipose homeostasis, and may have important implications for therapies that target costimulation in type 2 diabetes.
- Received July 12, 2013.
- Accepted November 11, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.